Key result
Low-dose L-NAME treatment (0.37 mmol/L) significantly reduced mortality and the severity of heart failure and myocardial necrosis in a murine model of coxsackievirus B3-induced myocarditis.
Why the study?
Does low-dose L-NAME improve survival and decrease myocardial injury in a murine model of coxsackievirus B3-induced myocarditis?
Population
Murine model of coxsackievirus B3-induced myocarditis
Comparison
Low concentration of N omega-nitro-L-arginine… vs Normal drinking water or higher concentration of…
Design
Preclinical
Follow-up
14 days
Authors
Loading...
Hypothesis-generating for NO inhibition in viral myocarditis; leaves open clinical translation pending human trials.
Does low-dose L-NAME improve survival and decrease myocardial injury in a murine model of coxsackievirus B3-induced myocarditis?
Inhibition of NO synthesis with low-dose L-NAME improves survival and reduces myocardial injury in a murine model of viral myocarditis, highlighting the pathogenic role of NO.
Mikami et al. (1997) studied Coxsackievirus B3-induced viral myocarditis. N omega-nitro-L-arginine methyl ester (L-NAME) vs. Normal drinking water was evaluated on Mortality and extent of myocardial injury. Low-dose L-NAME treatment (0.37 mmol/L) significantly reduced mortality and the severity of heart failure and myocardial necrosis in a murine model of coxsackievirus B3-induced myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: